ASKA Pharmaceutical Holdings Co.,Ltd. (TYO:4886)
2,930.00
+24.00 (0.83%)
May 29, 2026, 3:30 PM JST
TYO:4886 Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 10,126 | 10,603 | 13,738 | 14,505 | 12,103 |
Short-Term Investments | 893 | 555 | 3,500 | 3,400 | 5,000 |
Cash & Short-Term Investments | 11,019 | 11,158 | 17,238 | 17,905 | 17,103 |
Cash Growth | -1.25% | -35.27% | -3.72% | 4.69% | 62.67% |
Receivables | 15,955 | 15,090 | 15,579 | 15,217 | 14,482 |
Inventory | 29,181 | 26,333 | 20,402 | 17,687 | 15,060 |
Other Current Assets | 5,269 | 5,466 | 2,924 | 2,950 | 2,912 |
Total Current Assets | 61,424 | 58,047 | 56,143 | 53,759 | 49,557 |
Property, Plant & Equipment | 19,244 | 18,709 | 11,263 | 10,796 | 10,936 |
Long-Term Investments | 20,756 | 14,472 | 17,765 | 16,400 | 14,244 |
Goodwill | 2,354 | 4,361 | - | - | - |
Other Intangible Assets | 6,515 | 2,632 | 2,877 | 4,465 | 6,183 |
Long-Term Deferred Tax Assets | 2,085 | 2,312 | 2,696 | 1,717 | 2,376 |
Other Long-Term Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 112,379 | 100,534 | 90,745 | 87,138 | 83,297 |
Accounts Payable | 7,558 | 9,146 | 7,355 | 5,860 | 6,841 |
Accrued Expenses | 1,316 | 1,283 | 1,225 | 1,166 | 1,188 |
Short-Term Debt | 1,707 | 2,521 | 300 | 300 | 300 |
Current Portion of Long-Term Debt | 1,562 | 1,940 | 4,680 | 3,138 | 1,423 |
Current Income Taxes Payable | 8,020 | 6,367 | 8,690 | 4,947 | 4,867 |
Other Current Liabilities | 2,128 | 1,622 | 1,718 | 2,239 | 1,392 |
Total Current Liabilities | 22,291 | 22,879 | 23,968 | 17,650 | 16,011 |
Long-Term Debt | 8,165 | 6,441 | 4,505 | 9,185 | 12,323 |
Pension & Post-Retirement Benefits | 23 | 206 | - | 5,433 | 5,730 |
Other Long-Term Liabilities | 5,081 | 1,813 | 343 | 337 | 341 |
Total Liabilities | 35,560 | 31,339 | 28,816 | 32,605 | 34,405 |
Common Stock | 1,197 | 1,197 | 1,197 | 1,197 | 1,197 |
Additional Paid-In Capital | 31 | - | 1,848 | 1,847 | 1,867 |
Retained Earnings | 63,352 | 59,545 | 56,372 | 49,619 | 45,833 |
Treasury Stock | -658 | -704 | -3,287 | -3,350 | -3,479 |
Comprehensive Income & Other | 6,438 | 5,272 | 5,799 | 5,220 | 3,474 |
Total Common Equity | 70,360 | 65,310 | 61,929 | 54,533 | 48,892 |
Minority Interest | 6,459 | 3,885 | - | - | - |
Shareholders' Equity | 76,819 | 69,195 | 61,929 | 54,533 | 48,892 |
Total Liabilities & Equity | 112,379 | 100,534 | 90,745 | 87,138 | 83,297 |
Total Debt | 11,434 | 10,902 | 9,485 | 12,623 | 14,046 |
Net Cash (Debt) | -415 | 256 | 7,753 | 5,282 | 3,057 |
Net Cash Growth | - | -96.70% | 46.78% | 72.78% | - |
Net Cash Per Share | -14.62 | 9.03 | 273.83 | 187.05 | 107.75 |
Filing Date Shares Outstanding | 28.39 | 28.36 | 28.33 | 28.29 | 28.18 |
Total Common Shares Outstanding | 28.39 | 28.36 | 28.33 | 28.29 | 28.18 |
Working Capital | 39,133 | 35,168 | 32,175 | 36,109 | 33,546 |
Book Value Per Share | 2477.91 | 2302.59 | 2186.05 | 1927.97 | 1734.75 |
Tangible Book Value | 61,491 | 58,317 | 59,052 | 50,068 | 42,709 |
Tangible Book Value Per Share | 2165.57 | 2056.04 | 2084.49 | 1770.12 | 1515.37 |